Flag of the European Union EU Clinical Trials Register Help

Clinical trials for II

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    11,926 result(s) found for: II. Displaying page 93 of 597.
    «« First « Previous 89  90  91  92  93  94  95  96  97  Next» Last»»
    EudraCT Number: 2014-002672-86 Sponsor Protocol Number: Altshock Start Date*: 2015-04-20
    Sponsor Name:AO OSPEDALE NIGUARDA CA' GRANDA
    Full Title: PHASE II CLINICAL TRIAL FOR A STEPWISE PROGRESSION IN THE TREATMENT OF CARDIOGENIC SHOCK
    Medical condition: Patients affected by cardiogenic shock
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001638-37 Sponsor Protocol Number: COX2M3M Start Date*: 2022-03-28
    Sponsor Name:Semmelweis Egyetem Fogorvostudományi Kar Arc- Állcsont- Szájsebészeti és Fogászati Klinika, Budapest
    Full Title: Comparison of the preventive painkiller effect of etoricoxib and celecoxib after M3M surgery: A randomized, double-masked clinical trial
    Medical condition: postoperative pain
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-002134-14 Sponsor Protocol Number: 1.0 Start Date*: 2022-09-02
    Sponsor Name:Catharina Hospital Eindhoven
    Full Title: Intraperitoneal irinotecan with concomitant FOLFOX and bevacizumab for patients with unresectable colorectal peritoneal metastases – a phase II study
    Medical condition: Patients with peritoneal carcinomatosis of colorectal origin
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-001989-36 Sponsor Protocol Number: SIGN Start Date*: 2022-09-07
    Sponsor Name:Med. Univ. Wien, Klinik f. Innere Med I, Onkologie
    Full Title: Selective serotonin reuptake inhibition in patients with advanced gastroesophageal cancer receiving immunochemotherapy: a prospective phase II trial
    Medical condition: gastroesophageal cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-004981-14 Sponsor Protocol Number: OOI/KEMB/2006-2 Start Date*: 2006-12-20
    Sponsor Name:National Institute of Oncology, Budapest, Hungary
    Full Title: Phase II., non randomized, open study: inoperable gall bladder or biliary tract EGFR expressing carcinoma treatment with Erbitux and 5-fluorouracil, epiadriamycin, mitomycin containing combination ...
    Medical condition: Irresectable biliary tract cancer where palliation is the aim. It could be locally extanded and also metastatic cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002360-14 Sponsor Protocol Number: AK-2016-HHC1 Start Date*: 2016-09-29
    Sponsor Name:Rigshospitalet, Dapartment of of Clinical Physiology, Nuclear Medicine and PET
    Full Title: Phase II trial: PET/CT for staging advanced and localized oral and oropharyngeal cancer
    Medical condition: Oral squamous cell cancer (OSCC) with and with out local metastasis Oropharyngeal squamous cell cancer (OPSCC) with and with out local metastasis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073040 Metastatic oropharyngeal cancer LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030961 Oral cancer stage unspecified LLT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028801 Oropharyngeal, nasopharyngeal and tonsillar neoplasms malignant and unspecified HLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10031096 Oropharyngeal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001087-28 Sponsor Protocol Number: RC31/19/0511 Start Date*: 2020-12-29
    Sponsor Name:CHU Toulouse
    Full Title: Anti-IL6 receptor antibodies to reduce allo-sensitization post allograft nephrectomy ; a pilot phase II study
    Medical condition: kidney transplantation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10029116 Nephrectomy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-004801-11 Sponsor Protocol Number: 04-081 Start Date*: 2005-02-14
    Sponsor Name:Zealand Pharma A/S
    Full Title: A Phase II, Multicenter, Double-Blind, Efficacy, Safety, and Tolerability Study of ZP120 Administered as Short Term I.V. Infusion as Add-On Therapy in Patients with Subacute Decompensated Chronic H...
    Medical condition: Subacute decompensated chronic heart failure NYHA Class III-IV
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000996-98 Sponsor Protocol Number: CSL112_3001 Start Date*: 2018-09-05
    Sponsor Name:CSL Behring LLC
    Full Title: A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome
    Medical condition: Acute Coronary Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10000891 Acute myocardial infarction PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Temporarily Halted) LV (Completed) SE (Completed) PT (Completed) FI (Completed) BE (Completed) LT (Completed) DK (Completed) EE (Completed) DE (Completed) AT (Completed) CZ (Completed) NO (Completed) HU (Completed) FR (Completed) NL (Completed) ES (Restarted) SK (Completed) BG (Completed) GR (Completed) HR (Completed) IT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2006-004608-37 Sponsor Protocol Number: FER-CARS-02 Start Date*: 2007-07-27
    Sponsor Name:Vifor Pharma, Vifor (International) Ltd.
    Full Title: A randomised double-blind controlled phase III study to compare the efficacy and safety of intravenous ferric carboxymaltose (Ferinject®) with placebo in patients with chronic heart failure and iro...
    Medical condition: iron deficiency in patients with chronic heart failure
    Disease: Version SOC Term Classification Code Term Level
    8.1 10022970 Iron deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) IT (Completed) CZ (Completed) GR (Completed) SE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2019-000333-39 Sponsor Protocol Number: Darvadstrocel-3003 Start Date*: 2019-10-15
    Sponsor Name:Takeda Development Center Americas, Inc
    Full Title: A Follow-up of a Phase 3 Study to Evaluate the Long-term Safety and Efficacy of Darvadstrocel in the Treatment of Complex Perianal Fistula in Subjects With Crohn’s Disease Who Have Participated in ...
    Medical condition: Perianal fistulising Crohn´s disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10002156 Anal fistula PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) FR (Completed) HU (Completed) ES (Completed) BE (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-001600-64 Sponsor Protocol Number: RPC01-3102 Start Date*: 2015-10-14
    Sponsor Name:Celgene International II Sàrl
    Full Title: A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis
    Medical condition: Ulcerative colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) DE (Completed) GB (Completed) SK (Completed) HU (Trial now transitioned) BG (Trial now transitioned) NL (Completed) BE (Trial now transitioned) HR (Completed) LV (Completed) AT (Prematurely Ended) GR (Completed) ES (Prematurely Ended) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-003205-15 Sponsor Protocol Number: GO29527 Start Date*: 2015-11-30
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHE...
    Medical condition: NON−SMALL CELL LUNG CANCER
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10029514 Non-small cell lung cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) DE (Trial now transitioned) PT (Trial now transitioned) ES (Ongoing) NL (Ongoing) FR (Trial now transitioned) HU (Trial now transitioned) RO (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-005157-23 Sponsor Protocol Number: DART Start Date*: 2013-05-21
    Sponsor Name:Fondazione IRCCS Istituto Nazionale Tumori
    Full Title: A Phase I/II Study of Danusertib in Combination with Romidepsin in Adult Patients with Mature Peripheral T Cell Lymphoma (PTCL)
    Medical condition: (Ph I) Relapsed or refractory Hodgkin (HL) and Non Hodgkin lymphoma (NHL) in patients in the absence, unable ot who have been refused to undergo alternative salvage regimens. (Ph II) Relapsed or r...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10025319 Lymphomas Hodgkin's disease HLGT
    14.1 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    14.1 10005329 - Blood and lymphatic system disorders 10025322 Lymphomas non-Hodgkin's unspecified histology HLGT
    14.1 10005329 - Blood and lymphatic system disorders 10025321 Lymphomas non-Hodgkin's T-cell HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-005066-37 Sponsor Protocol Number: AC-052-415 Start Date*: 2006-03-15
    Sponsor Name:Actelion Pharmaceuticals Ltd.
    Full Title: COMPASS-1 / Hemodynamic effects of a single dose of sildenafil in symptomatic patients on bosentan treatment for pulmonary arterial hypertension – A multicenter, open-label, non-comparative, prospe...
    Medical condition: Symptomatic Pulmonary Arterial Hypertension (WHO functional class II-III) of the following types: - Idiopathic - Familial - Associated with: Corrected congenital s...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-019707-32 Sponsor Protocol Number: 1199.82 Start Date*: 2010-12-14
    Sponsor Name:Boehringer Ingelheim
    Full Title: LUME-Lung 3. A Phase I/II study of continuous oral treatment with BIBF 1120 added to standard gemcitabine/cisplatin therapy in first line NSCLC patients with squamous cell histology.
    Medical condition: Advanced Non Small Cell Lung Cancer (recurrent or stage IIIB/IV) with squamous cell histology.
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001184 Adenocarcinoma of lung stage IV LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001183 Adenocarcinoma of lung stage IIIB LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001177 Adenocarcinoma of lung recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Prematurely Ended) PT (Prematurely Ended) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-004230-28 Sponsor Protocol Number: 1368-0005 Start Date*: 2018-02-27
    Sponsor Name:Boehringer Ingelheim RCV GmbH & Co KG
    Full Title: A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of BI 655130 (SPESOLIMAB) Induction Therapy in patients with moderate-to-severely ...
    Medical condition: Moderate-to-severely active ulcerative colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) BE (Prematurely Ended) DE (Completed) GB (Completed) ES (Prematurely Ended) NL (Prematurely Ended) DK (Prematurely Ended) GR (Prematurely Ended) HU (Completed) CZ (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-001549-26 Sponsor Protocol Number: TRASTS Start Date*: 2014-11-03
    Sponsor Name:GEIS
    Full Title: Phase I-II prospective trial, multicenter, open label, exploring the combination of Trabectedin plus Radiotherapy in Soft Tissue Sarcoma patients.
    Medical condition: Soft Tissue Sarcoma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-002602-52 Sponsor Protocol Number: BAY80-6946/16349 Start Date*: 2012-10-19
    Sponsor Name:Bayer AG
    Full Title: Open-label, uncontrolled Phase II trial of intravenous PI3K inhibitor BAY 80-6946 in patients with relapsed, indolent or aggressive Non-Hodgkin’s lymphomas
    Medical condition: Patients with relapsed, indolent or aggressive Non-Hodgkin’s lymphomas or patients with follicular lymphoma relapsed after or refractory to standard therapy.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029600 Non-Hodgkin's lymphoma recurrent PT
    20.0 100000004851 10029621 Non-Hodgkin's lymphomas unspecified histology indolent HLT
    20.0 100000004851 10029608 Non-Hodgkin's lymphomas unspecified histology aggressive HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FI (Completed) DE (Completed) BE (Completed) ES (Completed) IT (Completed) SE (Completed) PL (Completed) AT (Completed) PT (Completed) HU (Completed) DK (Prematurely Ended) IE (Completed) GR (Completed) LU (Completed)
    Trial results: View results
    EudraCT Number: 2014-003032-39 Sponsor Protocol Number: CLEE011X2110C Start Date*: 2014-12-26
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A phase Ib/II study of the ALK inhibitor ceritinib in combination with the CDK4/6 inhibitor LEE011 in patients with ALK-positive Non-small Cell Lung Cancer
    Medical condition: Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 89  90  91  92  93  94  95  96  97  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jul 05 04:24:32 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA